Palmitoyl-L-carnitine-d9 (chloride)
(Synonyms: CAR 16:0-d9; C16:0 Carnitine-d9; L-Carnitine hexadecanoyl ester-d9; L-Carnitine palmitoyl ester-d9; Hexadecanoyl-L-carnitine-d9; L-Hexadecanoylcarnitine-d9; L-Palmitoylcarnitine-d9) 目录号 : GC92159Palmitoyl-L-carnitine-d9 is intended for use as an internal standard for the quantification of palmitoyl-L-carnitine by GC- or LC-MS.
Sample solution is provided at 25 µL, 10mM.
Palmitoyl-L-carnitine-d9 is intended for use as an internal standard for the quantification of palmitoyl-L-carnitine by GC- or LC-MS. Palmitoyl-L-carnitine is a long-chain acylcarnitine and an isomer of palmitoyl-DL-carnitine and palmitoyl-D-carnitine .1 Palmitoyl-L-carnitine is transported into mitochondria via carnitine palmitoyl transferase II to deliver palmitate for fatty acid oxidation and energy production.2 It inhibits lecithin:cholesterol acyltransferase activity in isolated rat, but not human, plasma when used at a concentration of 500 µM.3 Serum and hepatic levels of palmitoyl-L-carnitine are increased in mice during cold exposure, and it is taken up by brown adipose tissue.4 Palmitoyl-L-carnitine also protects against age-induced cold sensitivity in mice.
References:
[1]. Bezaire, V., Bruce, C.R., Heigenhauser, G.J.F., et al.Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: Essential role in fatty acid oxidationAm. J. Physiol. Endocrinol. Metab.290(3)E509-E515(2006).
[2]. El-Hayek, R., Valdivia, C., Valdivia, H.H., et al.Activation of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum by palmitoyl carnitineBiophys. J.65(2)779-789(1993).
[3]. Bell, F.P.Carnitine esters: Novel inhibitors of plasma lecithin: Cholesterol acyltransferase in experimental animals but not in man (Homo sapiens)Int. J. Biochem.15(2)133-136(1983).
[4]. Simcox, J., Geoghegan, G., Maschek, J.A., et al.Global analysis of plasma lipids identifies liver-derived acylcarnitines as a fuel source for brown fat thermogenesisCell Metab.26(3)509-522(2017).
Cas No. | SDF | ||
别名 | CAR 16:0-d9; C16:0 Carnitine-d9; L-Carnitine hexadecanoyl ester-d9; L-Carnitine palmitoyl ester-d9; Hexadecanoyl-L-carnitine-d9; L-Hexadecanoylcarnitine-d9; L-Palmitoylcarnitine-d9 | ||
化学名 | 2R-3-carboxy-N,N,N-tri(methyl-d3)-2-[(1-oxohexadecyl)oxy]-1-propanaminium, inner salt, monochloride | ||
Canonical SMILES | CCCCC[C@@H](O)/C=C/[C@H]([C@H]1CCCCCCC(O)=O)C=CC1=O | ||
分子式 | C23H37D9NO4•Cl | 分子量 | 445.1 |
溶解度 | Acetonitrile: Slightly soluble: 0.1-1 mg/ml,Water: Slightly soluble: 0.1-1 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.2467 mL | 11.2334 mL | 22.4669 mL |
5 mM | 0.4493 mL | 2.2467 mL | 4.4934 mL |
10 mM | 0.2247 mL | 1.1233 mL | 2.2467 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet